Asian populations, but thought to be less common in those of African descent. Larger series describe a bimodal age distribution, with peak incidence in the third and seventh decades. 6, 7 Both male and female patients are affected, though there is preponderance for male patients in those presenting in early adulthood, and slight female preponderance in those presenting in later life. In renal biopsy series, it accounts for $15% of cases of crescentic GN, 8 though it is a rare cause of end-stage renal disease (ESRD) in both adults and children. 9, 10 Single-center series suggest that 15 to 20% of pulmonary-renal syndromes are caused by anti-GBM disease.
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Pathogenesis
The accepted paradigm of autoimmune disease pathogenesis proposes that an environmental insult to a genetically susceptible individual results in miscommunication between the innate and adaptive immune systems, breakdown of tolerance, and the recognition of self-antigens as the target of a damaging immunologic response. 14 The principle target of the autoimmune response in anti-GBM disease is the noncollagenous domain of the α-3 chain of type IV collagen, α3(IV)NC1, and though there is increasing understanding of the genetic and environmental factors that contribute to disease, the precise molecular mechanisms of disease induction are not fully understood.
Genetics
Anti-GBM disease has strong positive and negative human leukocyte antigen (HLA) associations. Inheritance of HLA-DR15 is consistently associated with disease susceptibility in Caucasian and Asian populations, whereas HLR-DR1, -DR7, and -DR9 are negatively associated with disease risk.
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Indeed, HLA-DR1 and -DR7 appear to confer a "dominant" protective affect if coinherited with HLA-DR15. A recent series of studies using mice transgenic for human HLA molecules (and lacking murine MHC Class II) confirm these epidemiologic observations: HLA-DR15 transgenic mice are susceptible to induction of experimental anti-GBM disease, whereas mice transgenic for either HLA-DR1 or both HLA-DR15 and DR1 are resistant. 18, 19 These studies suggest that presentation of the immunodominant T cell epitope in the distinct binding registries of HLA-DR15 and -DR1 can differentially induce conventional and tolerogenic T cell responses, respectively, thus accounting for the dominant protective effect of HLA-DR1 via induction of antigen-specific regulatory T cells, even when coinherited with the HLA-DR15 susceptibility allele. In contrast to other antibody-associated glomerular diseases, such as antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) and membranous nephropathy, where genome-wide association studies have identified polymorphisms in the target autoantigen associated with disease susceptibility, a small study did not identify any polymorphisms in COL4A3, the gene encoding the anti-GBM disease autoantigen, related to disease predisposition. Exposure to pulmonary irritants is associated with the development of lung hemorrhage in anti-GBM disease, which occurs in nearly all patients who smoke but less frequently in nonsmokers. 28 Hydrocarbon exposure has likewise been implicated in disease onset, 29, 30 and there are case reports of anti-GBM disease after use of inhaled recreational drugs including cocaine and amphetamine. [31] [32] [33] It has been suggested that pulmonary irritants may increase capillary permeability, thus predisposing to alveolar bleeding, or that they may modify or expose sequestered basement membrane antigens to immune detection, resulting in disease enhancement. Exposure to the drug alemtuzumab, a lymphocyte-depleting monoclonal anti-CD52 mAb used in the treatment of multiple sclerosis, has recently been implicated in developing anti-GBM disease (and other autoimmune phenomena). 34, 35 It has been proposed that T cell reconstitution after alemtuzumab is driven largely by homeostatic expansion of cells that have escaped deletion (rather than by thymopoiesis), resulting in a T cell pool that is enriched for autoreactive cells and predisposition to clinical autoimmunity.
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Autoimmunity
The principle target of the autoimmune response in anti-GBM disease is the noncollagenous domain of the α-3 chain of type IV collagen, α3(IV)NC1. 37, 38 The collagen IV family consists of six genetically distinct α-chains (α1-6) that trimerize with each other to make specific triple-helical protomers: α1α1α2, α3α4α5, and α5α5α6 that then polymerize to form the collagen IV network. The expression of the α3α4α5 protomer is restricted to the glomerular and alveolar basement membranes (with the α1α1α2 protomer being most abundantly expressed elsewhere), thus accounting for the clinical presentation of pulmonary-renal syndrome in anti-GBM disease.
Compelling evidence for the direct pathogenicity of anti-GBM antibodies was provided by adoptive transfer experiments, wherein immunoglobulins eluted from kidneys taken from humans with anti-GBM disease were administered to nonhuman primates, resulting in the development of GN in recipients. 39 The pathogenicity of anti-GBM antibodies has since been replicated in several species and experimental models. In clinical studies, antibody concentration and affinity correlate with the severity of renal disease at presentation. [40] [41] [42] [43] Antibody subclass has also been associated with disease severity, with an increased proportion of immunoglobulin G (IgG)1 and IgG3 autoantibody in patients with more severe disease. 44, 45 Treatment to rapidly remove circulating antibodies with plasmapheresis is associated with improved clinical outcomes in anti-GBM disease, 46 and if renal transplantation is performed in the presence of detectable antibody, disease may recur immediately in the graft.
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All patients have autoantibodies reactive to α3(IV)NC1, and a proportion also shows reactivity to α5(IV)NC1 and α4(IV) NC1, demonstrated upon antibody elution from diseased kidney tissue. 48 It has been suggested that reactivity to other collagen chains arises after a primary response to α3(IV)NC1 via a process of intermolecular epitope spreading. Circulating anti-α1(IV)NC1 antibodies have also been described, and associated with the development of pulmonary involvement.
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While anti-GBM disease is regarded as a prototypic autoantibody-mediated disease, T cells clearly have a role in disease induction and persistence, as evidenced by the strong HLA association, the presence of affinity-matured and class-switched autoantibodies, and the phenomenon of "epitope spreading". Indeed, T cells autoreactive to α3(IV)NC1 can be detected in patients at higher levels than in healthy controls, and their levels wane as disease resolves. [50] [51] [52] In addition to providing "help" for autoreactive B cells, effector T cells may also mediate tissue injury in anti-GBM disease. CD4þ and CD8þ T cells can be identified in glomerular lesions in anti-GBM disease 53, 54 (though it is not clear that they are antigen specific) and evidence from experimental animal models suggests that disease can be induced in the absence of significant humoral immunity. [55] [56] [57] Immunization with an immunodominant T cell epitope alone is sufficient to induce both GN and autoantibody production in mice, 18 suggesting that injurious T cell responses may incite glomerular damage, and that the humoral responses required for full disease expression develop as secondary phenomenon to this initial injury. It is striking, however, that circulating low-level natural autoantibodies to α3(IV)NC1 can be identified in healthy individuals. 58 These antibodies have the same epitope specificity as those found in patients, though IgG2 and IgG4 subclasses predominate. Another study found that anti-GBM antibodies may be detected in patients several months before the onset of clinical disease. 59 In addition, autoreactive T cells can be identified in healthy individuals. 51 Thus, it is possible that central immunological tolerance to α3(IV) NC1 is incomplete (despite its expression in human thymus 60 ) and that autoimmunity to this antigen may lie dormant or suppressed by regulatory mechanisms in healthy individuals, until an inciting event triggers disease onset. One proposed trigger is "conformational transition" of the α3(IV)NC1 autoantigen, within which two key B cell epitopes have been identified. 48 In normal circumstances, these epitopes are cryptic, being buried within the quaternary structure of the NC1 domains. Disruption or modification of this quaternary structure, perhaps by pulmonary irritants or infection, may expose these epitopes and allow a fulminant anti-GBM response to develop. A similar mechanism may also account for the association of anti-GBM disease with other renal disorders, such as AAV and membranous GN, 61, 62 which may likewise disrupt GBMs.
Clinical Presentation
The majority of patients present with RPGN (►Table 1). That is, a brisk declines in kidney function in association with glomerular hematuria and proteinuria. RPGN is typically defined as >50% loss of glomerular filtration rate in less than 3 months, though in anti-GBM disease the deterioration can be much more rapid, occurring over a few days or weeks. As such, a short prodrome of nonspecific constitutional . Approximately 40 to 60% of patients have concurrent alveolar hemorrhage (►Table 1), which is more common in young male patients and in current smokers. 28 It may present with cough, dyspnea, and hemoptysis, or be apparent radiographically. A disproportionately severe iron-deficient anemia should also alert to the possibility of covert underlying alveolar bleeding. A small proportion of patients (<10%) may present with isolated pulmonary disease in the absence of renal involvement. The presence of extrarenal/pulmonary manifestations is uncommon in anti-GBM disease, and may suggest an alternative cause of pulmonary-renal syndrome, or that the patient has a coexisting ANCA.
Investigation and Diagnosis
Securing rapid diagnosis in cases of renal-pulmonary syndrome is essential so that directed therapy can be initiated promptly. 63 Thus, several imaging and laboratory tests may be arranged concurrently (►Table 2). Central to the diagnosis of anti-GBM disease is the demonstration of anti-GBM antibodies, either in circulation or in tissue, and confirmation of GN and/or alveolar hemorrhage.
Detection of Anti-GBM Antibodies
In routine clinical practice, circulating antibodies are detected using commercially available enzyme linked immunosorbent assays (ELISAs) or bead-based immunoassays, which are accepted to have high sensitivity and specificity. 64 These assays generally use purified or recombinant human or animal GBM preparations as antigen, and are typically optimized to detect IgG antibodies, thus rare cases of IgA-or IgM-mediated anti-GBM disease may not be identified. 
Renal Biopsy Findings
Crescentic GN is the hallmark of anti-GBM disease in the kidney. 21 A crescent is defined at two or more layers of proliferating cells in Bowman's space, thought to arise as a result of severe glomerular inflammation, rupture of the GBM, extravasation of fibrin and cells into the urinary space, and reactive proliferation of parietal epithelial cells lining Bowman's capsule. In anti-GBM disease, crescents are usually widespread, affecting >50% of glomeruli in 80% of patients,
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and of similar age and activity (►Fig. 1), reflecting abrupt disease onset, and distinguishing it from AAV, where a mix of cellular, fibrocellular, and fibrous crescents are usually observed. Acute tubular injury may be seen, along with red cell casts in tubular lumens, though interstitial and tubular atrophy are not prominent unless there is preexisting renal disease. Vascular lesions are not typical of anti-GBM disease, This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
unless there is an associated ANCA-mediated process, in which case necrotizing arteritis or venulitis may be seen in the smalland medium-sized vessels in the kidney.
Diagnosis of Alveolar Hemorrhage
There are no uniform diagnostic criteria for the diagnosis of diffuse alveolar hemorrhage, and diagnosis is often made on a combination of clinical, radiological, and laboratory findings. This may account for the variable frequency of lung hemorrhage described in clinical series of anti-GBM disease (►Table 1). Radiology (►Fig. 2): Plain chest radiography may demonstrate nonspecific diffuse opacification patterns with occasional predilection for the mid-zones and apical and costophrenic sparing. 67 On high-resolution computed tomography, acute alveolar filling with blood may give groundglass opacifications, which may progress to frank consolidation, again with peripheral sparing. As hemorrhage is resorbed in the pulmonary interstitium, later imaging may show reticular or nodular appearances.
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Bronchoalveolar lavage: Acute alveolar hemorrhage may be indicated by the finding of hemorrhagic bronchoalveolar lavage fluid, classically with increasing blood content on successive washes. After 2 to 3 days, alveolar macrophages convert hemoglobin to hemosiderin, and these hemosiderinladen cells may persist in the lung for several weeks, being evident on Perls staining of bronchoalveolar samples.
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Threshold proportions of 20 to 30% hemosiderin-laden cells of the total macrophage count have been suggested to be strongly indicative of diffuse alveolar hemorrhage.
Pulmonary function testing: An increase in diffusing capacity of the lung for carbon monoxide (KCO) has been reported in alveolar hemorrhage in anti-GBM disease, being attributed to increased CO uptake by intra-alveolar erythrocytes.
70 However, this finding may not be present in all cases, 71 perhaps due to ventilation-perfusion mismatch in a proportion, such that measurement of KCO may have useful positive, but not negative, predictive value. Pathology: Lung biopsy is rarely performed in cases of alveolar hemorrhage in anti-GBM disease. When undertaken, it is likely to show alveolar lumens filled with erythrocytes and hemosiderin-laden cells. Pulmonary capillaritis may be present, with features of fibrinoid necrosis of capillary walls and inflammation and edema of the alveolar interstitium.
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Treatment
Recommended treatment for anti-GBM disease includes plasmapheresis, to rapidly remove pathogenic autoantibody, along with cyclophosphamide and corticosteroids, to inhibit further autoantibody production and to reduce tissue inflammation and damage. 73 Our standard treatment regimen is summarized in ►Table 3.
Evidence supporting the use of plasmapheresis in anti-GBM disease comes from observational studies that indicate improved renal outcomes and patient survival compared with cohorts treated with immunosuppression alone, 46, 74, 75 and one small randomized study that suggested favorable outcomes and more rapid clearance of anti-GBM antibodies with plasmapheresis. Cyclophosphamide is the most commonly used immunosuppressive treatment in anti-GBM disease. A majority of reports have used daily oral dosing. The equivalence of pulsed intravenous therapy for remission induction in AAV is well established, though has not been studied in anti-GBM disease. Of note, a recent nationwide study from France suggests that patient outcomes may be superior with daily oral dosing, and so this remains our preferred approach in anti-GBM disease.
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Rituximab has emerged as a useful therapeutic agent in the treatment of many autoimmune renal diseases. There are $20 case reports of rituximab use in anti-GBM disease in the literature, 78 often as an adjunct to conventional therapy. It appears to be associated with consistent immunological responses, though clinical outcomes are variable. While it may facilitate more rapid clearance of pathogenic autoantibody, rituximab will have no direct effects on autoreactive T cells, monocytes, and neutrophils, which experimental models suggest contribute to disease pathogenesis. There is insufficient evidence to recommend its use as sole first-line therapy, though it may be considered an alternative where there are strong contraindications to the use of cyclophosphamide, or as an adjunct in severe disease. There are individual case reports of mycophenolate mofetil and calcineurin-inhibitor use in the treatment of anti-GBM disease, 79-81 though there is likewise insufficient evidence to recommend their routine use. In addition to immunosuppression, prophylactic treatments for steroid-induced side effects and opportunistic infection are recommended, including those for Pneumocystis jiroveci pneumonia, peptic ulcer disease, oropharyngeal candidiasis, and osteoporosis.
In patients presenting with severe disease, immediate organ support may be required. Approximately half of patients will have an indication for acute renal replacement therapy at the time of diagnosis (►Table 1). One small series suggests that 11% of patients presenting with alveolar hemorrhage require artificial ventilation. 71 In severe lung hemorrhage, extracorporeal membrane oxygenation may be considered, and appears to be associated with favorable outcome despite the requirement for systemic anticoagulation in the setting of alveolar bleeding (►Table 4).
Outcomes
Using the combination of plasmapheresis along with immunosuppressive therapy, the majority of lung hemorrhage is responsive to treatment. In the largest published series to consistently employ this approach, 90% of patients with lung hemorrhage had recovery. 7 A selected series of alveolar hemorrhage in anti-GBM disease likewise showed high response rates to treatment, with all patients recovering from pulmonary manifestations. 71 Data on long-term respiratory outcomes in anti-GBM disease, however, are scarce. One small study suggested that patients who had lung hemorrhage have significantly reduced KCO compared with controls without lung involvement. 82 However, a subsequent larger series suggested that long-term respiratory sequela after lung hemorrhage in anti-GBM disease are not common. 71 This is in contrast to AAV, where interstitial lung disease is increasingly recognized as an important long-term complication, especially in patients positive for MPO-ANCA, suggesting distinct mechanisms of pulmonary injury in these dieseases.
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Renal responses to treatment are being more variable. Levy et al found that the majority of patients who do not require immediate renal replacement therapy (RRT) had a favorable renal outcome, with 95 and 91% renal survival at 1 and 5 years, respectively, in those with a presenting serum creatinine of <500 µmol/L. 7 In those presenting with creatinine >500 µmol/L (but not requiring RRT), the corresponding renal survival rates were 82 and 50%, respectively. In those presenting with an immediate need for RRT, however, long-term renal survival was poor. Several series suggest that less than 10% of cases will recover independent renal function, with only 8% renal survival at 1 year in the Hammersmith series (►Table 1). Several studies have aimed to identify reliable predictors of renal outcome. Severity of renal dysfunction at presentation, the proportion of glomeruli affected by crescents, and oligoanuria at presentation have each been associated with renal outcome. 7, 21, 85 A recent worldwide, multicenter study recruited 123 cases with renal-biopsy proven anti-GBM GN, with median follow-up of 3.9 years, making it the largest histopathological study in anti-GBM disease to date. 86 It confirmed previous observations of most favorable outcomes in patients presenting with creatinine of <500 µmol/L. Independent predictors of ESRD were dialysis requirement at presentation, reduced proportion of normal glomeruli, and increased interstitial infiltrate on kidney biopsy. Of note, no patient with 100% crescents or >50% sclerotic glomeruli recovered renal function. Anti-GBM disease is usually a "one-hit" phenomenon, and relapses are rare. Even in the absence of immunosuppression, there is a progressive fall in autoantibody titers and numbers of autoreactive T cells, accompanied by the development of a CD25þ suppressor T cell subset, suggesting that immunological tolerance to α3(IV)NC1 is reinstated. 87 When relapses do occur, it is often in association with ongoing exposure to pulmonary irritants, and their avoidance once identified is essential for long-term management.
Transplantation in Anti-GBM Disease
Renal transplantation should not be performed in the presence of circulating anti-GBM antibodies, as there is a high risk of disease recurrence. 47 Most centers therefore recommend a 6-month period of sustained negative testing for anti-GBM antibodies before undertaking transplantation surgery. With these conditions, recurrent disease in renal allografts is rare, and patient and allograft survivals are at least comparable to, if not better than, those transplanted for other causes of ESRD.
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Diffuse alveolar hemorrhage is generally responsive to treatment, and not associated with long-term pulmonary complications. As such, we are aware of only one case of anti-GBM disease requiring lung transplantation, which had good long-term outcome.
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Isolated Pulmonary Involvement in Anti-GBM Disease
Presentation with isolated or predominant pulmonary involvement in anti-GBM disease is recognized, though uncommon, being estimated to occur in <10% of patients in larger series. Such cases are not extensively characterized, perhaps reflecting publication bias from renal centers, though there are small case series. 90, 91 Some patients may have mild urinary abnormalities and minor proliferative changes on renal biopsy, but with preserved excretory renal function, while others may have no clinical or histological evidence of renal inflammation. Renal biopsy, however, may still reveal linear deposits of immunoglobulin, including in those patients who are negative by serological assay. A small series from Sweden recently described four young female patients who presented with severe alveolar hemorrhage and favorable renal outcome, who were seronegative for circulating anti-GBM antibodies by conventional assay. 92 They were, however, found to have circulating IgG4 anti-GBM antibodies by dedicated ELISA, and confirmed on kidney biopsy. Together, these findings suggest that clinical presentation in anti-GBM disease may be influenced by differences in antibody subclass or antigen target, and also highlight the need to consider variant anti-GBM disease in cases of "idiopathic" pulmonary hemorrhage.
"Double Positive" ANCA and Anti-GBM Disease A significant proportion of patients with anti-GBM disease will also have detectable ANCA in circulation, occurring in 20 to 40% of cases in larger series (►Table 1). Conversely, one study suggested that up to 5% of patients with ANCA have detectable anti-GBM antibodies. 93 This incidence of "double positivity" occurs at much higher rates that would be expected by chance alone, though the mechanism of association is not understood. It appears that double positive patients initially present with the severe disease manifestations of anti-GBM disease, with high rates of severe renal failure and diffuse alveolar hemorrhage requiring intensive treatment with plasmapheresis and immunosuppression. During long-term follow-up, however, they demonstrate a tendency to relapse at the frequency of patients with AAV, and thus they require long-term maintenance immunosuppression, unlike patients with isolated anti-GBM disease.
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Conclusion
Anti-GBM disease is a rare disorder, though an important differential in patients presenting with RPGN, pulmonary hemorrhage, or a combined renal-pulmonary syndrome. The clinical features may be nonspecific, thus a high index of suspicion is required. Rapid serological testing may facilitate early diagnosis, though a proportion of patients are negative for circulating antibodies, including those presenting with predominant pulmonary involvement. In these cases, renal biopsy may identify deposited anti-GBM antibody, with or without evidence of GN, and allow prompt initiation of directed treatment with plasmapheresis and immunosuppression that may successfully treat life-threatening alveolar hemorrhage and prevent long-term renal failure.
